General Report

Hemophagocytic syndrome caused by visceral leishmaniasis in children:a report of four cases and literature review

  • Wanyi LI ,
  • Yongjun WANG ,
  • Donghai LIU ,
  • Xuemei DONG ,
  • Wenyuan WANG ,
  • Qian HAN
Expand
  • 1. The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China
    2. Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, Gansu, China
    3. Pediatric Clinical Medicine Research Center of Gansu Province, Lanzhou 730050, Gansu, China

Received date: 2022-01-15

  Online published: 2023-02-16

Abstract

Objective To analyze the clinical data of children with visceral leishmaniasis (VL) presenting as hemophagocytic syndrome (HPS) in order to improve the clinical diagnosis and treatment level. Methods The clinical data of 4 children with HPS secondary to VL hospitalized from March 2020 to March 2021 were retrospectively analyzed, and were compared with the literature data. Results All the 4 patients showed persistent fever, splenomegaly and cytopenia. Combined with relevant examinations, the patients were diagnosed with HPS. Considering the epidemiological factors, the examination of VL was performed, and the results showed that rK39 test was positive in 4 cases, and Leishmanias donovani was detected by bone marrow smear in 3 cases. Sodium stibogluconate treatment in the four children was successful. A review of the literature on VL-HLH in the past 5 years showed that compared with primary HLH, children with VL-HLH had higher ferritin and increased erythrocyte sedimentation rate. Compared with VL, VL-HLH may be more prone to pancytopenia, hypertriglyceridemia, hyperserum ferriminemia, and lower absolute monocyte counts. Amphotericin B may be more efficient and safer than sodium stibogluconate for the treatment of VL-HLH.Conclusions For children with a history of staying in the epidemic area, the possibility of VL should be considered in the comprehensive analysis of the primary etiology of HPS, and rK39 test and bone marrow smear examination should be performed at the same time. Early and accurate treatment of the cause can avoid aggravation of the disease and the toxic side effects caused by chemotherapy.

Cite this article

Wanyi LI , Yongjun WANG , Donghai LIU , Xuemei DONG , Wenyuan WANG , Qian HAN . Hemophagocytic syndrome caused by visceral leishmaniasis in children:a report of four cases and literature review[J]. Journal of Clinical Pediatrics, 2023 , 41(1) : 54 -59 . DOI: 10.12372/jcp.2023.22e0096

References

[1] Risma KA, Marsh RA. Hemophagocytic lymphohistiocytosis:clinical presentations and diagnosis[J]. J Allergy Clin Immunol Pract, 2019, 7(3):824-832.
[2] 中华人民共和国卫生部. 黑热病诊断标准.中华人民共和国卫生行业标准:WS 258-2006[S]. (2006-04-07)[2021-08-10].http://www.nhc.gov.cn/xxgk/pages/wsbzsearch.jsp.
[3] Henter JI, Horne A, Aricó M, et al. HLH-2004:Diag-nostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
[4] 中华传染病杂志编辑委员会. 中国利什曼原虫感染诊断和治疗专家共识[J]. 中华传染病杂志, 2017, (35):513-518.
[5] 噬血细胞综合征中国专家联盟, 中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(2):91-95.
[6] Mottaghipisheh H, Kalantar K, Amanati A, et al. Comparison of the clinical features and outcome of children with hemophagocytic lymphohistiocytosis (HLH) secondary to visceral leishmaniasis and primary HLH:a single-center study[J]. BMC Infect Dis, 2021, 21(1):732.
[7] Brum NFF, Coelho JS, Carvalho LS, et al. Hemophagocytic lymphohistiocytosis and visceral leishmaniasis in children:a series of cases and literature review[J]. Rev Paul Pediatr, 2021, 40:e2020269.
[8] Carvalho FHG, Lula JF, Teles LF, et al. Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in an endemic area in the north of Minas Gerais, Brazil[J]. Rev Soc Bras Med Trop, 2020, 53:e20190491.
[9] Guo F, Kang L, Xu M. A case of pediatric visceral leishmaniasis-related hemophagocytic lymphohistiocytosis diagnosed by mNGS[J]. Int J Infect Dis, 2020, 97:27-29.
[10] 索涛莉, 郝国平, 王晓欢, 等. 儿童黑热病继发噬血细胞综合征单中心临床分析[J]. 山西医药杂志, 2020, 49(13):1721-1723.
[11] 代伟, 曹蕾, 张福琴. 婴儿内脏利什曼病继发噬血细胞综合征1例[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(5):513.
[12] 张真珍. 黑热病相关噬血细胞综合征1例[J]. 兰州大学学报:医学版, 2018, 44(6):82-84.
[13] López Marcos M, Ruiz Sáez B, Vílchez Pérez JS, et al. Distinct laboratory and clinical features of secondary hemophagocytic lymphohistiocytosis in pediatric visceral leishmaniasis:a retrospective analysis of 127 children in Andalusia, Spain (2004-2019)[J]. Pediatr Infect Dis J, 2021, 40(6):525-530.
[14] Magill A J. Leishmania species:visceral(Kala-Azar),Cutaneous, and mucosal leishmaniasis - sciencedirect[J]. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition), 2015, 2(1):3091-3107.
[15] 汪俊云, 高春花. 《黑热病诊断标准》解读[J]. 中国血吸虫病防治杂志, 2017, 29(5):541-543.
[16] 郑灿军, 薛垂召, 伍卫平, 等. 我国2005-2015年黑热病报告病例流行特征分析[J]. 中华流行病学杂志, 2017, 38(4):431-434
[17] 李凡, 陈生邦, 冯宇, 等. 2005-2007年甘肃省黑热病流行因素分析[J]. 疾病预防控制通报, 2009, 24(5):37-38.
[18] Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis:differences and similarities[J]. Br J Haematol, 2016, 174(2):203-217.
[19] Colomba C, Carlo PD, Scarlata F, et al. Visceral leishmaniasis, hypertriglyceridemia and secondary hemophagocytic lymphohistiocytosis[J]. Infection, 2016, 44(3):1-2.
[20] Blázquez-Gamero D, Domínguez-Pinilla N, Chicharro C, et al. Hemophagocytic lymphohistiocytosis in children with visceral leishmaniasis[J]. Pediatr Infect Dis J, 2015, 34(6):667-669.
[21] Avau A, Put K, Wouters CH, et al. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis[J]. Cytokine Growth Factor Rev, 2015, 26(1):35-45.
[22] 郭霞, 陈娜, 王天有, 等. 儿童内脏利什曼病相关性噬血细胞性淋巴组织细胞增生症四例临床分析[J]. 中华儿科杂志, 2011, 49(7):550-553.
[23] Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease[J]. Cochrane Database Syst Rev, 2014, 6(6):CD009135.
[24] Bode SF, Bogdan C, Beutel K, et al. Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area[J]. J Pediatr, 2014, 165(1):147-153.
[25] Clavijo A, Salvador T, Moral L, et al. Hemophagocytic lymphohistiocytosis in children with visceral leishmaniasis[J]. Pediatr Infect Dis J, 2016, 35(6):713-714.
[26] Scalzone M, Ruggiero A, Mastrangelo S, et al. Hemophagocytic lymphohistiocytosis and visceral leishmaniasis in children:case report and systematic review of literature[J]. J Infect Dev Ctries, 2016, 10(1):103-108.
[27] Gagnaire MH, Galambrun C, Stéphan JL. Hemophagocytic syndrome:a misleading complication of visceral leishmaniasis in children--a series of 12 cases[J]. Pediatrics, 2000, 106(4):E58.
[28] Bezerra GF, Meneses GC, Jacinto VN, et al. Preliminary study for new markers of early tubuloglomerular injury and renal inflammation in patients with visceral leishmaniasis receiving liposomal amphotericin B treatment[J]. Am J Trop Med Hyg, 2022, 106(4):1191-1195.
[29] Ren D, Cao W, Liu X, et al. Case report:use of liposomal amphotericin B in low doses in patients with visceral leishmaniasis[J]. Front Med (Lausanne), 2021, 8:766400.
Outlines

/